Circulating mir‐320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk

miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 144; no. 11; pp. 2746 - 2761
Main Authors Fortunato, Orazio, Borzi, Cristina, Milione, Massimo, Centonze, Giovanni, Conte, Davide, Boeri, Mattia, Verri, Carla, Moro, Massimo, Facchinetti, Federica, Andriani, Francesca, Roz, Luca, Caleca, Laura, Huber, Veronica, Cova, Agata, Camisaschi, Chiara, Castelli, Chiara, Cancila, Valeria, Tripodo, Claudio, Pastorino, Ugo, Sozzi, Gabriella
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.06.2019
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN0020-7136
1097-0215
1097-0215
DOI10.1002/ijc.31988

Cover

Abstract miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell‐type specific expression pattern and topography of several miRNAs such as mir‐145 in fibroblasts, mir‐126 in endothelial cells, mir‐133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de‐regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir‐320a secreted by neutrophils of high‐risk heavy‐smokers promoted an M2‐like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell‐autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression. What's new? microRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. However, little is known on the origin of circulating miRNAs and their mechanisms of action. This study found a multifactorial and non‐epithelial cell‐autonomous origin of circulating miRNAs associated with lung cancer risk. The findings also suggest a link between an immunosuppressive and pro‐tumorigenic microenvironment and modulation of circulating miRNAs associated with lung cancer risk. The authors propose a novel mechanism whereby miRNA released by neutrophils induce macrophage polarization to support lung cancer growth, highlighting the potential for reprogramming macrophages toward an anti‐tumor polarization.
AbstractList miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell‐type specific expression pattern and topography of several miRNAs such as mir‐145 in fibroblasts, mir‐126 in endothelial cells, mir‐133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de‐regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir‐320a secreted by neutrophils of high‐risk heavy‐smokers promoted an M2‐like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell‐autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression. What's new? microRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. However, little is known on the origin of circulating miRNAs and their mechanisms of action. This study found a multifactorial and non‐epithelial cell‐autonomous origin of circulating miRNAs associated with lung cancer risk. The findings also suggest a link between an immunosuppressive and pro‐tumorigenic microenvironment and modulation of circulating miRNAs associated with lung cancer risk. The authors propose a novel mechanism whereby miRNA released by neutrophils induce macrophage polarization to support lung cancer growth, highlighting the potential for reprogramming macrophages toward an anti‐tumor polarization.
miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell-type specific expression pattern and topography of several miRNAs such as mir-145 in fibroblasts, mir-126 in endothelial cells, mir-133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de-regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir-320a secreted by neutrophils of high-risk heavy-smokers promoted an M2-like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell-autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression.miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell-type specific expression pattern and topography of several miRNAs such as mir-145 in fibroblasts, mir-126 in endothelial cells, mir-133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de-regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir-320a secreted by neutrophils of high-risk heavy-smokers promoted an M2-like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell-autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression.
miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell‐type specific expression pattern and topography of several miRNAs such as mir‐145 in fibroblasts, mir‐126 in endothelial cells, mir‐133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de‐regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir‐320a secreted by neutrophils of high‐risk heavy‐smokers promoted an M2‐like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell‐autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression. What's new? microRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. However, little is known on the origin of circulating miRNAs and their mechanisms of action. This study found a multifactorial and non‐epithelial cell‐autonomous origin of circulating miRNAs associated with lung cancer risk. The findings also suggest a link between an immunosuppressive and pro‐tumorigenic microenvironment and modulation of circulating miRNAs associated with lung cancer risk. The authors propose a novel mechanism whereby miRNA released by neutrophils induce macrophage polarization to support lung cancer growth, highlighting the potential for reprogramming macrophages toward an anti‐tumor polarization.
miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell-type specific expression pattern and topography of several miRNAs such as mir-145 in fibroblasts, mir-126 in endothelial cells, mir-133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de-regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir-320a secreted by neutrophils of high-risk heavy-smokers promoted an M2-like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell-autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression.
Author Sozzi, Gabriella
Facchinetti, Federica
Caleca, Laura
Verri, Carla
Conte, Davide
Castelli, Chiara
Borzi, Cristina
Tripodo, Claudio
Huber, Veronica
Boeri, Mattia
Andriani, Francesca
Camisaschi, Chiara
Pastorino, Ugo
Fortunato, Orazio
Roz, Luca
Centonze, Giovanni
Cancila, Valeria
Moro, Massimo
Cova, Agata
Milione, Massimo
AuthorAffiliation 1 Tumor Genomics Unit, Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
5 Tumor Immunology Unit, Department of Health Science, Human Pathology Section University of Palermo School of Medicine Milan Italy
4 Unit of Immunotherapy of Human Tumors, Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
3 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Milan Italy
2 Anatomic Pathology Unit, Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
6 Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
AuthorAffiliation_xml – name: 1 Tumor Genomics Unit, Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
– name: 4 Unit of Immunotherapy of Human Tumors, Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
– name: 2 Anatomic Pathology Unit, Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
– name: 6 Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
– name: 5 Tumor Immunology Unit, Department of Health Science, Human Pathology Section University of Palermo School of Medicine Milan Italy
– name: 3 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Milan Italy
Author_xml – sequence: 1
  givenname: Orazio
  surname: Fortunato
  fullname: Fortunato, Orazio
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 2
  givenname: Cristina
  surname: Borzi
  fullname: Borzi, Cristina
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 3
  givenname: Massimo
  surname: Milione
  fullname: Milione, Massimo
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 4
  givenname: Giovanni
  surname: Centonze
  fullname: Centonze, Giovanni
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 5
  givenname: Davide
  surname: Conte
  fullname: Conte, Davide
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 6
  givenname: Mattia
  surname: Boeri
  fullname: Boeri, Mattia
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 7
  givenname: Carla
  surname: Verri
  fullname: Verri, Carla
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 8
  givenname: Massimo
  surname: Moro
  fullname: Moro, Massimo
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 9
  givenname: Federica
  surname: Facchinetti
  fullname: Facchinetti, Federica
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 10
  givenname: Francesca
  surname: Andriani
  fullname: Andriani, Francesca
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 11
  givenname: Luca
  surname: Roz
  fullname: Roz, Luca
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 12
  givenname: Laura
  surname: Caleca
  fullname: Caleca, Laura
  organization: Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
– sequence: 13
  givenname: Veronica
  surname: Huber
  fullname: Huber, Veronica
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 14
  givenname: Agata
  surname: Cova
  fullname: Cova, Agata
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 15
  givenname: Chiara
  surname: Camisaschi
  fullname: Camisaschi, Chiara
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 16
  givenname: Chiara
  surname: Castelli
  fullname: Castelli, Chiara
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 17
  givenname: Valeria
  surname: Cancila
  fullname: Cancila, Valeria
  organization: University of Palermo School of Medicine
– sequence: 18
  givenname: Claudio
  surname: Tripodo
  fullname: Tripodo, Claudio
  organization: University of Palermo School of Medicine
– sequence: 19
  givenname: Ugo
  surname: Pastorino
  fullname: Pastorino, Ugo
  organization: Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori
– sequence: 20
  givenname: Gabriella
  orcidid: 0000-0001-9360-6914
  surname: Sozzi
  fullname: Sozzi, Gabriella
  email: gabriella.sozzi@istitutotumori.mi.it
  organization: Fondazione IRCCS Istituto Nazionale dei Tumori
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30426475$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAQxy1URLeFAy-ALHGBQ9rxRxLngoRWfBQVcendcpzZXW8TO9hJq73xCDwjT4KXLRVUgpNlzW9-mpn_CTnywSMhzxmcMQB-7rb2TLBGqUdkwaCpC-CsPCKLXIOiZqI6JicpbQEYK0E-IccCJK9kXS7I9dJFO_dmcn5NBxd_fPsuOBg6xjCECRN1wzD7kOZxjJiSu0E6GBvDuDHrXP3M6bhBH6bdiNSkFKwzE3b01k0b2s_ZaY23GGl06fopebwyfcJnd-8puXr_7mr5sbj88uFi-faysFIKVXCGrBFVha1ilmNjWlN3XHFRi7Zaya6TjFe1BKVkK9DU1uZvx2FlUTSdEqfkzUE7zu2AnUU_RdPrMbrBxJ0Oxum_K95t9Drc6KpsgFcsC17dCWL4OmOa9OCSxb43HsOcNGdCSAlNWWb05QN0G-bo83aacxC1YpLvhS_-nOh-lN8xZOD1AciXTSni6h5hoPcR6xyx_hVxZs8fsNZNOb-wX8b1_-u4dT3u_q3WF5-Wh46ffPG5yA
CitedBy_id crossref_primary_10_1172_JCI158352
crossref_primary_10_1186_s13046_021_02040_3
crossref_primary_10_1186_s12951_024_03088_x
crossref_primary_10_1016_j_jtho_2023_08_019
crossref_primary_10_3389_fimmu_2024_1452078
crossref_primary_10_1080_21655979_2022_2061295
crossref_primary_10_1093_carcin_bgad061
crossref_primary_10_3390_ijms20071611
crossref_primary_10_1016_j_healun_2023_08_011
crossref_primary_10_1039_D1BM01797G
crossref_primary_10_3390_cancers11091380
crossref_primary_10_3892_ijo_2020_5108
crossref_primary_10_3390_cancers13071493
crossref_primary_10_3390_ph15030297
crossref_primary_10_1002_1878_0261_13336
crossref_primary_10_1002_jcp_28744
crossref_primary_10_1016_j_lungcan_2019_04_001
crossref_primary_10_3390_ijms21197117
crossref_primary_10_1002_iid3_341
crossref_primary_10_3892_etm_2022_11477
crossref_primary_10_62347_JAYK5667
crossref_primary_10_3389_fonc_2022_911613
crossref_primary_10_1016_j_annonc_2022_01_008
crossref_primary_10_1002_1878_0261_13036
crossref_primary_10_2217_bmm_2023_0215
crossref_primary_10_1166_jbn_2022_3352
crossref_primary_10_3390_cancers11060888
crossref_primary_10_2174_0122115366296148240530072346
crossref_primary_10_3390_biomedicines11030736
crossref_primary_10_3390_ph14020089
crossref_primary_10_1016_j_semcdb_2021_04_001
crossref_primary_10_1155_2024_7484645
crossref_primary_10_1631_jzus_B1900452
crossref_primary_10_3389_fcell_2021_643942
crossref_primary_10_1007_s12672_025_02054_9
crossref_primary_10_3390_ijms25042331
crossref_primary_10_1016_j_biopha_2020_110369
crossref_primary_10_1016_j_yexmp_2020_104411
crossref_primary_10_1093_bib_bbac397
crossref_primary_10_1016_j_prp_2022_154053
crossref_primary_10_1186_s13046_019_1122_2
crossref_primary_10_3390_ijms22020746
crossref_primary_10_1128_mSystems_00724_20
crossref_primary_10_3389_fimmu_2020_01391
crossref_primary_10_1016_j_lanepe_2024_101070
crossref_primary_10_1016_j_jid_2022_01_030
crossref_primary_10_3390_ph13120438
crossref_primary_10_1111_cas_16113
crossref_primary_10_3390_cancers14020435
crossref_primary_10_1016_j_intimp_2019_105880
crossref_primary_10_1158_1055_9965_EPI_22_0689
crossref_primary_10_1016_j_prp_2023_154906
crossref_primary_10_3390_ijms23105297
Cites_doi 10.1007/s10555-007-9066-y
10.1158/1541-7786.MCR-12-0634-T
10.1093/annonc/mdx033
10.1038/nrc1877
10.1016/j.rmed.2015.02.006
10.4049/jimmunol.166.7.4446
10.1038/nrc1256
10.7554/eLife.05005
10.1093/nar/gkw116
10.1183/09031936.02.00089802
10.3332/ecancer.2017.717
10.1101/gr.082701.108
10.1016/j.intimp.2010.08.012
10.1186/1476-4598-12-154
10.1056/NEJMoa1504627
10.1158/1940-6207.CAPR-11-0370
10.1111/jth.12730
10.1038/nri2448
10.1038/ncomms14381
10.1016/j.it.2016.01.004
10.1038/ncb2396
10.1038/srep35250
10.1172/JCI59643
10.1073/pnas.1100048108
10.1038/nri978
10.1007/s12032-011-9923-y
10.1164/rccm.200607-984PP
10.1002/emmm.201100154
10.1097/CEJ.0b013e328351e1b6
10.4049/jimmunol.164.9.4659
10.1136/jclinpath-2015-203005
10.1080/15384047.2017.1281497
10.18632/oncotarget.8676
10.1183/09031936.98.12020380
10.1513/pats.200809-100TH
10.1016/S0140-6736(03)14188-8
10.1038/nm.3394
10.1111/liv.13495
10.1038/nrclinonc.2014.5
10.1038/s41571-018-0111-2
10.1002/emmm.201100209
10.1038/cddis.2014.507
10.1016/S0002-9440(10)65704-5
10.18632/oncotarget.9943
10.18632/oncotarget.5210
10.1158/0008-5472.CAN-14-3781
10.1038/sj.bjc.6605642
10.1080/0284186X.2018.1465585
10.3390/molecules19033038
10.3892/ol.2017.5863
10.1038/nri3088
10.1093/jnci/djv063
10.18632/oncotarget.19996
10.1093/nar/gku461
10.1186/s12864-015-2097-9
10.1200/JCO.2013.50.4357
10.4049/jimmunol.0903879
ContentType Journal Article
Copyright 2018 The Authors. published by John Wiley & Sons Ltd on behalf of UICC
2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
2019 UICC
Copyright_xml – notice: 2018 The Authors. published by John Wiley & Sons Ltd on behalf of UICC
– notice: 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
– notice: 2019 UICC
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TO
7U9
H94
K9.
7X8
5PM
DOI 10.1002/ijc.31988
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

MEDLINE
AIDS and Cancer Research Abstracts
CrossRef
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Circulating mir‐320a promotes immunosuppressive macrophages
EISSN 1097-0215
EndPage 2761
ExternalDocumentID PMC6590261
30426475
10_1002_ijc_31988
IJC31988
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Fondazione Umberto Veronesi
– fundername: Cariplo Foundation
  funderid: 2015 n.2015‐0901
– fundername: Ministry of Health
  funderid: NIH/U01CA166905; RF‐2010
– fundername: Italian Association for Cancer Research
  funderid: 12162; 16847; 18812; 14318; 15928
– fundername: NCI NIH HHS
  grantid: U01 CA166905
– fundername: Cariplo Foundation
  grantid: 2015 n.2015‐0901
– fundername: Ministry of Health
  grantid: NIH/U01CA166905; RF‐2010
– fundername: Italian Association for Cancer Research
  grantid: 12162; 16847; 18812; 14318; 15928
GroupedDBID ---
-~X
.3N
.GA
05W
0R~
10A
1L6
1OB
1OC
1ZS
24P
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIAGR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RX1
RYL
SUPJJ
TEORI
UB1
UDS
V2E
V8K
V9Y
W2D
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
XPP
XV2
ZZTAW
~IA
~WT
.55
.GJ
.Y3
31~
3O-
53G
8WZ
A6W
AANHP
AAYXX
ABEFU
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADNMO
AGQPQ
AHEFC
AI.
AIQQE
ASPBG
AVWKF
AZFZN
BDRZF
CITATION
EX3
FEDTE
GLUZI
HF~
HVGLF
LW6
M6P
PALCI
RJQFR
SAMSI
VH1
WOW
X7M
Y6R
ZGI
ZXP
AAHHS
ACCFJ
ADZOD
AEEZP
AEQDE
AIWBW
AJBDE
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TO
7U9
H94
K9.
7X8
5PM
ID FETCH-LOGICAL-c4438-21e19366eb81c2e9aba7d282373b6f4dd4126740884b3ea7cc267d20fce39d83
IEDL.DBID DR2
ISSN 0020-7136
1097-0215
IngestDate Thu Aug 21 18:34:34 EDT 2025
Thu Jul 10 23:41:28 EDT 2025
Fri Jul 25 09:27:16 EDT 2025
Thu Apr 03 06:56:32 EDT 2025
Mon Sep 15 11:46:55 EDT 2025
Thu Apr 24 23:02:01 EDT 2025
Sun Sep 21 06:25:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords lung cancer
microenvironment
microRNA
Language English
License Attribution-NonCommercial
2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4438-21e19366eb81c2e9aba7d282373b6f4dd4126740884b3ea7cc267d20fce39d83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
O.F designed the study, acquired, analyzed and drafted the article; C.B.; G.C.; D.C.; F.F.; M.B.; C.V.; M.Mo.; L.C.;F.A.; V.H.; A.C.; C.Cam.; V.C. acquired and analyzed data; revised critically the article; M.Mi.; L.R.; C.T.; C.Cas.; U.P.; G.S. designed the study, interpreted data, revised critically the article. All the authors approved the final version of the study.
ORCID 0000-0001-9360-6914
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.31988
PMID 30426475
PQID 2203781421
PQPubID 105430
PageCount 16
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6590261
proquest_miscellaneous_2133440955
proquest_journals_2203781421
pubmed_primary_30426475
crossref_primary_10_1002_ijc_31988
crossref_citationtrail_10_1002_ijc_31988
wiley_primary_10_1002_ijc_31988_IJC31988
PublicationCentury 2000
PublicationDate 1 June 2019
PublicationDateYYYYMMDD 2019-06-01
PublicationDate_xml – month: 06
  year: 2019
  text: 1 June 2019
  day: 01
PublicationDecade 2010
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Hoboken
PublicationTitle International journal of cancer
PublicationTitleAlternate Int J Cancer
PublicationYear 2019
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2010; 10
2017; 8
2012; 122
2015; 75
2010; 102
2004; 4
2011; 11
2008; 8
2008; 5
2015; 109
2010; 184
2015; 107
2012; 14
2013; 8
2016; 37
1998; 153
2013; 19
2001; 61
2014; 5
2013; 11
2013; 12
2007; 175
2015; 373
2003; 3
2012; 29
2000; 164
2014; 19
2009; 19
2012; 21
2014; 12
1998; 12
2018; 38
2014; 11
2003; 362
2007; 26
2016; 44
2001; 166
2015; 16
2015; 4
2017; 28
2006; 6
2011; 3
2014; 42
2015; 68
2016; 6
2016; 7
2011; 108
2002; 20
2017; 11
2015; 20
2017; 13
2017; 18
2012; 4
2012; 5
2018; 15
2014; 32
2018; 57
e_1_2_6_51_1
e_1_2_6_53_1
e_1_2_6_32_1
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_59_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_17_1
e_1_2_6_55_1
e_1_2_6_15_1
e_1_2_6_38_1
e_1_2_6_57_1
e_1_2_6_43_1
e_1_2_6_20_1
e_1_2_6_41_1
e_1_2_6_60_1
e_1_2_6_9_1
e_1_2_6_5_1
e_1_2_6_7_1
Schmielau J (e_1_2_6_30_1) 2001; 61
e_1_2_6_24_1
e_1_2_6_49_1
e_1_2_6_3_1
e_1_2_6_22_1
e_1_2_6_45_1
e_1_2_6_26_1
e_1_2_6_47_1
e_1_2_6_52_1
e_1_2_6_54_1
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_18_1
e_1_2_6_39_1
e_1_2_6_56_1
e_1_2_6_16_1
e_1_2_6_37_1
e_1_2_6_58_1
e_1_2_6_42_1
e_1_2_6_21_1
e_1_2_6_40_1
e_1_2_6_61_1
Quatromoni JG (e_1_2_6_50_1) 2012; 4
e_1_2_6_8_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_48_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_29_1
e_1_2_6_44_1
e_1_2_6_27_1
Sestini S (e_1_2_6_28_1) 2015; 20
e_1_2_6_46_1
Massion PP (e_1_2_6_4_1) 2013; 8
References_xml – volume: 20
  start-page: 32868
  year: 2015
  end-page: 77
  article-title: Circulating microRNA signature as liquid‐biopsy to monitor lung cancer in low‐dose computed tomography screening
  publication-title: Oncotarget
– volume: 13
  start-page: 3247
  year: 2017
  end-page: 52
  article-title: MicroRNA‐320a is downregulated in non‐small cell lung cancer and suppresses tumor cell growth and invasion by directly targeting insulin‐like growth factor 1 receptor
  publication-title: Oncol Lett
– volume: 12
  start-page: 1764
  year: 2014
  end-page: 75
  article-title: Platelets in inflammation and immunity
  publication-title: J Thromb Haemost
– volume: 57
  start-page: 1225
  year: 2018
  end-page: 31
  article-title: Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
  publication-title: Acta Oncol
– volume: 5
  start-page: 492
  year: 2012
  end-page: 7
  article-title: Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies
  publication-title: Cancer Prev Res (Phila)
– volume: 175
  start-page: 547
  year: 2007
  end-page: 53
  article-title: Lung cancer and lung stem cells: strange bedfellows?
  publication-title: Am J Respir Crit Care Med
– volume: 122
  start-page: 787
  year: 2012
  end-page: 95
  article-title: Macrophage plasticity and polarization: in vivo veritas
  publication-title: J Clin Invest
– volume: 362
  start-page: 593
  year: 2003
  end-page: 7
  article-title: Early lung‐cancer detection with spiral CT and positron emission tomography in heavy smokers: 2‐year results
  publication-title: Lancet
– volume: 5
  start-page: e1564
  year: 2014
  article-title: Mir‐660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2‐p53 interaction
  publication-title: Cell Death Dis
– volume: 4
  start-page: 376
  year: 2012
  end-page: 89
  article-title: Tumor‐associated macrophages: function, phenotype, and link to prognosis in human lung cancer
  publication-title: Am J Transl Res
– volume: 6
  start-page: 392
  year: 2006
  end-page: 401
  article-title: Fibroblasts in cancer
  publication-title: Nat Rev Cancer
– volume: 3
  start-page: 495
  year: 2011
  end-page: 503
  article-title: A serum circulating miRNA diagnostic test to identify asymptomatic high‐risk individuals with early stage lung cancer
  publication-title: EMBO Mol Med
– volume: 21
  start-page: 308
  year: 2012
  end-page: 15
  article-title: Annual or biennial CT screening versus observation in heavy smokers: 5‐year results of the MILD trial
  publication-title: Eur J Cancer Prev
– volume: 102
  start-page: 1555
  year: 2010
  end-page: 77
  article-title: Guidelines for the welfare and use of animals in cancer research
  publication-title: Br J Cancer
– volume: 68
  start-page: 661
  year: 2015
  end-page: 4
  article-title: A novel semi‐automated in situ hybridisation protocol for microRNA detection in paraffin embedded tissue sections
  publication-title: J Clin Pathol
– volume: 42
  start-page: 7528
  year: 2014
  end-page: 38
  article-title: Lessons from miR‐143/145: the importance of cell‐type localization of miRNAs
  publication-title: Nucleic Acids Res
– volume: 61
  start-page: 4756
  year: 2001
  end-page: 60
  article-title: Activated granulocytes and granulocyte‐derived hydrogen peroxide are the underlying mechanism of suppression of t‐cell function in advanced cancer patients
  publication-title: Cancer Res
– volume: 166
  start-page: 4446
  year: 2001
  end-page: 55
  article-title: Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses
  publication-title: J Immunol
– volume: 38
  start-page: 125
  year: 2018
  end-page: 35
  article-title: Neuropilin‐1 regulated by miR‐320 contributes to the growth and metastasis of cholangiocarcinoma cells
  publication-title: Liver Int
– volume: 164
  start-page: 4659
  year: 2000
  end-page: 64
  article-title: Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1‐mediated inflammation
  publication-title: J Immunol
– volume: 12
  start-page: 154
  year: 2013
  article-title: Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase
  publication-title: Mol Cancer
– volume: 8
  start-page: 83913
  year: 2017
  end-page: 24
  article-title: Selective secretion of microRNAs from lung cancer cells via extracellular vesicles promotes CAMK1D‐mediated tube formation in endothelial cells
  publication-title: Oncotarget
– volume: 8
  start-page: 958
  year: 2008
  end-page: 69
  article-title: Exploring the full spectrum of macrophage activation
  publication-title: Nat Rev Immunol
– volume: 3
  start-page: 23
  year: 2003
  end-page: 35
  article-title: Alternative activation of macrophages
  publication-title: Nat Rev Immunol
– volume: 32
  start-page: 768
  year: 2014
  end-page: 73
  article-title: Clinical utility of a plasma‐based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study
  publication-title: J Clin Oncol
– volume: 184
  start-page: 6545
  year: 2010
  end-page: 51
  article-title: LAG‐3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites
  publication-title: J Immunol
– volume: 4
  start-page: 71
  year: 2004
  end-page: 8
  article-title: Tumour‐educated macrophages promote tumour progression and metastasis
  publication-title: Nat Rev Cancer
– volume: 4
  year: 2015
  article-title: Predicting effective microRNA target sites in mammalian mRNAs
  publication-title: Elife
– volume: 19
  start-page: 1423
  year: 2013
  end-page: 37
  article-title: Microenvironmental regulation of tumor progression and metastasis
  publication-title: Nat Med
– volume: 26
  start-page: 281
  year: 2007
  end-page: 90
  article-title: Hypoxia: a key regulator of angiogenesis in cancer
  publication-title: Cancer Metastasis Rev
– volume: 20
  start-page: 1449
  year: 2002
  end-page: 56
  article-title: Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro
  publication-title: Eur Respir J
– volume: 4
  start-page: 143
  year: 2012
  end-page: 59
  article-title: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
  publication-title: EMBO Mol Med
– volume: 107
  start-page: djv063
  year: 2015
  article-title: miR‐test: a blood test for lung cancer early detection
  publication-title: J Natl Cancer Inst
– volume: 19
  start-page: 3038
  year: 2014
  end-page: 54
  article-title: Assessment of circulating microRNAs in plasma of lung cancer patients
  publication-title: Molecules
– volume: 11
  start-page: 750
  year: 2011
  end-page: 61
  article-title: Transcriptional regulation of macrophage polarization: enabling diversity with identity
  publication-title: Nat Rev Immunol
– volume: 7
  start-page: 29275
  year: 2016
  end-page: 86
  article-title: MiR‐320a inhibits gastric carcinoma by targeting activity in the FoxM1‐P27KIP1 axis
  publication-title: Oncotarget
– volume: 14
  start-page: 159
  year: 2012
  end-page: 67
  article-title: Reprogramming of the tumour microenvironment by stromal PTEN‐regulated miR‐320
  publication-title: Nat Cell Biol
– volume: 8
  start-page: S6
  year: 2013
  article-title: Biomarker‐driven programs for lung cancer screening (abstract)
  publication-title: J Thorac Oncol
– volume: 7
  start-page: 49470
  year: 2016
  end-page: 80
  article-title: Decreased expression of microRNA‐320a promotes proliferation and invasion of non‐small cell lung cancer cells by increasing VDAC1 expression
  publication-title: Oncotarget
– volume: 18
  start-page: 142
  year: 2017
  end-page: 51
  article-title: MiR‐320a effectively suppresses lung adenocarcinoma cell proliferation and metastasis by regulating STAT3 signals
  publication-title: Cancer Biol Ther
– volume: 109
  start-page: 803
  year: 2015
  end-page: 12
  article-title: MicroRNA as tools and therapeutics in lung cancer
  publication-title: Respir Med
– volume: 12
  start-page: 380
  year: 1998
  end-page: 6
  article-title: Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease
  publication-title: Eur Respir J
– volume: 15
  start-page: 748
  year: 2018
  end-page: 62
  article-title: Hyperprogressive disease: recognizing a novel pattern to improve patient management
  publication-title: Nat Rev Clin Oncol
– volume: 10
  start-page: 1325
  year: 2010
  end-page: 34
  article-title: Neutrophils: Cinderella of innate immune system
  publication-title: Int Immunopharmacol
– volume: 28
  start-page: 1117
  year: 2017
  end-page: 23
  article-title: European cancer mortality predictions for the year 2017, with focus on lung cancer
  publication-title: Ann Oncol
– volume: 153
  start-page: 1903
  year: 1998
  end-page: 12
  article-title: Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity
  publication-title: Am J Pathol
– volume: 108
  start-page: 3713
  year: 2011
  end-page: 8
  article-title: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer
  publication-title: Proc Natl Acad Sci USA
– volume: 11
  start-page: 717
  year: 2017
  article-title: Circulating and tissue biomarkers in early‐stage non‐small cell lung cancer
  publication-title: Ecancermedicalscience
– volume: 16
  start-page: 849
  year: 2015
  article-title: Novel method to detect microRNAs using chip‐based QuantStudio 3D digital PCR
  publication-title: BMC Genomics
– volume: 11
  start-page: 145
  year: 2014
  end-page: 56
  article-title: Clinical relevance of circulating cell‐free microRNAs in cancer
  publication-title: Nat Rev Clin Oncol
– volume: 6
  start-page: 35250
  year: 2016
  article-title: Epithelial cell‐derived microvesicles activate macrophages and promote inflammation via microvesicle‐containing microRNAs
  publication-title: Sci Rep
– volume: 75
  start-page: 3636
  year: 2015
  end-page: 49
  article-title: Microenvironment‐modulated metastatic CD133+/CXCR4+/EpCAM‐ lung cancer‐initiating cells sustain tumor dissemination and correlate with poor prognosis
  publication-title: Cancer Res
– volume: 29
  start-page: 618
  year: 2012
  end-page: 26
  article-title: High expression of serum miR‐21 and tumor miR‐200c associated with poor prognosis in patients with lung cancer
  publication-title: Med Oncol
– volume: 5
  start-page: 811
  year: 2008
  end-page: 5
  article-title: Smoking and lung cancer: the role of inflammation
  publication-title: Proc Am Thorac Soc
– volume: 37
  start-page: 208
  year: 2016
  end-page: 20
  article-title: The nature of myeloid‐derived suppressor cells in the tumor microenvironment
  publication-title: Trends Immunol
– volume: 11
  start-page: 638
  year: 2013
  end-page: 50
  article-title: Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations
  publication-title: Mol Cancer Res
– volume: 44
  start-page: 3865
  year: 2016
  end-page: 77
  article-title: Distribution of miRNA expression across human tissues
  publication-title: Nucleic Acids Res
– volume: 8
  start-page: 14381
  year: 2017
  article-title: Neutrophils dominate the immune cell composition in non‐small cell lung cancer
  publication-title: Nat Commun
– volume: 19
  start-page: 92
  year: 2009
  end-page: 105
  article-title: Most mammalian mRNAs are conserved targets of microRNAs
  publication-title: Genome Res
– volume: 373
  start-page: 123
  year: 2015
  end-page: 35
  article-title: Nivolumab versus Docetaxel in advanced squamous‐cell non‐small‐cell lung cancer
  publication-title: N Engl J Med
– ident: e_1_2_6_34_1
  doi: 10.1007/s10555-007-9066-y
– ident: e_1_2_6_17_1
  doi: 10.1158/1541-7786.MCR-12-0634-T
– ident: e_1_2_6_2_1
  doi: 10.1093/annonc/mdx033
– ident: e_1_2_6_35_1
  doi: 10.1038/nrc1877
– ident: e_1_2_6_5_1
  doi: 10.1016/j.rmed.2015.02.006
– ident: e_1_2_6_44_1
  doi: 10.4049/jimmunol.166.7.4446
– ident: e_1_2_6_47_1
  doi: 10.1038/nrc1256
– ident: e_1_2_6_21_1
  doi: 10.7554/eLife.05005
– ident: e_1_2_6_26_1
  doi: 10.1093/nar/gkw116
– volume: 61
  start-page: 4756
  year: 2001
  ident: e_1_2_6_30_1
  article-title: Activated granulocytes and granulocyte‐derived hydrogen peroxide are the underlying mechanism of suppression of t‐cell function in advanced cancer patients
  publication-title: Cancer Res
– ident: e_1_2_6_43_1
  doi: 10.1183/09031936.02.00089802
– ident: e_1_2_6_3_1
  doi: 10.3332/ecancer.2017.717
– ident: e_1_2_6_22_1
  doi: 10.1101/gr.082701.108
– ident: e_1_2_6_39_1
  doi: 10.1016/j.intimp.2010.08.012
– ident: e_1_2_6_40_1
  doi: 10.1186/1476-4598-12-154
– ident: e_1_2_6_60_1
  doi: 10.1056/NEJMoa1504627
– ident: e_1_2_6_13_1
  doi: 10.1158/1940-6207.CAPR-11-0370
– ident: e_1_2_6_33_1
  doi: 10.1111/jth.12730
– ident: e_1_2_6_41_1
  doi: 10.1038/nri2448
– ident: e_1_2_6_37_1
  doi: 10.1038/ncomms14381
– ident: e_1_2_6_48_1
  doi: 10.1016/j.it.2016.01.004
– ident: e_1_2_6_52_1
  doi: 10.1038/ncb2396
– ident: e_1_2_6_42_1
  doi: 10.1038/srep35250
– ident: e_1_2_6_31_1
  doi: 10.1172/JCI59643
– ident: e_1_2_6_8_1
  doi: 10.1073/pnas.1100048108
– ident: e_1_2_6_57_1
  doi: 10.1038/nri978
– ident: e_1_2_6_46_1
  doi: 10.1007/s12032-011-9923-y
– ident: e_1_2_6_25_1
  doi: 10.1164/rccm.200607-984PP
– ident: e_1_2_6_9_1
  doi: 10.1002/emmm.201100154
– ident: e_1_2_6_16_1
  doi: 10.1097/CEJ.0b013e328351e1b6
– ident: e_1_2_6_59_1
  doi: 10.4049/jimmunol.164.9.4659
– ident: e_1_2_6_20_1
  doi: 10.1136/jclinpath-2015-203005
– ident: e_1_2_6_55_1
  doi: 10.1080/15384047.2017.1281497
– ident: e_1_2_6_51_1
  doi: 10.18632/oncotarget.8676
– ident: e_1_2_6_49_1
  doi: 10.1183/09031936.98.12020380
– ident: e_1_2_6_12_1
  doi: 10.1513/pats.200809-100TH
– ident: e_1_2_6_15_1
  doi: 10.1016/S0140-6736(03)14188-8
– ident: e_1_2_6_29_1
  doi: 10.1038/nm.3394
– ident: e_1_2_6_56_1
  doi: 10.1111/liv.13495
– ident: e_1_2_6_6_1
  doi: 10.1038/nrclinonc.2014.5
– ident: e_1_2_6_61_1
  doi: 10.1038/s41571-018-0111-2
– ident: e_1_2_6_45_1
  doi: 10.1002/emmm.201100209
– ident: e_1_2_6_23_1
  doi: 10.1038/cddis.2014.507
– ident: e_1_2_6_38_1
  doi: 10.1016/S0002-9440(10)65704-5
– ident: e_1_2_6_53_1
  doi: 10.18632/oncotarget.9943
– volume: 20
  start-page: 32868
  year: 2015
  ident: e_1_2_6_28_1
  article-title: Circulating microRNA signature as liquid‐biopsy to monitor lung cancer in low‐dose computed tomography screening
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5210
– ident: e_1_2_6_36_1
  doi: 10.1158/0008-5472.CAN-14-3781
– ident: e_1_2_6_24_1
  doi: 10.1038/sj.bjc.6605642
– ident: e_1_2_6_7_1
  doi: 10.1080/0284186X.2018.1465585
– ident: e_1_2_6_18_1
  doi: 10.3390/molecules19033038
– ident: e_1_2_6_54_1
  doi: 10.3892/ol.2017.5863
– ident: e_1_2_6_58_1
  doi: 10.1038/nri3088
– ident: e_1_2_6_11_1
  doi: 10.1093/jnci/djv063
– ident: e_1_2_6_27_1
  doi: 10.18632/oncotarget.19996
– ident: e_1_2_6_14_1
  doi: 10.1093/nar/gku461
– ident: e_1_2_6_19_1
  doi: 10.1186/s12864-015-2097-9
– ident: e_1_2_6_10_1
  doi: 10.1200/JCO.2013.50.4357
– ident: e_1_2_6_32_1
  doi: 10.4049/jimmunol.0903879
– volume: 4
  start-page: 376
  year: 2012
  ident: e_1_2_6_50_1
  article-title: Tumor‐associated macrophages: function, phenotype, and link to prognosis in human lung cancer
  publication-title: Am J Transl Res
– volume: 8
  start-page: S6
  year: 2013
  ident: e_1_2_6_4_1
  article-title: Biomarker‐driven programs for lung cancer screening (abstract)
  publication-title: J Thorac Oncol
SSID ssj0011504
Score 2.530944
Snippet miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2746
SubjectTerms Animals
Cancer
Carcinogenesis
Carcinogenesis - immunology
Cell Line, Tumor
Circulating MicroRNA - blood
Circulating MicroRNA - metabolism
Endothelial cells
Female
Fibroblasts
Gene Expression Profiling
Gene Expression Regulation, Neoplastic - immunology
Health risk assessment
Humans
Immunosuppression
Leukocytes (granulocytic)
Leukocytes (neutrophilic)
Lung - pathology
Lung cancer
Lung Neoplasms - blood
Lung Neoplasms - genetics
Lung Neoplasms - immunology
Lung Neoplasms - pathology
Macrophages
Macrophages - immunology
Macrophages - metabolism
Male
Medical research
Mice
Mice, SCID
microenvironment
microRNA
MicroRNAs - blood
MicroRNAs - metabolism
miRNA
Molecular Cancer Biology
Neutrophils
Neutrophils - immunology
Neutrophils - metabolism
Paracrine signalling
Phenotypes
Skeletal muscle
Stat4 protein
STAT4 Transcription Factor - genetics
STAT4 Transcription Factor - metabolism
Tobacco Smoking - blood
Tobacco Smoking - immunology
Tumor Escape - genetics
Xenograft Model Antitumor Assays
Title Circulating mir‐320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.31988
https://www.ncbi.nlm.nih.gov/pubmed/30426475
https://www.proquest.com/docview/2203781421
https://www.proquest.com/docview/2133440955
https://pubmed.ncbi.nlm.nih.gov/PMC6590261
Volume 144
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VHioutJTX9iWDOPSSNnG8diJO1dKqVFqEUJF6QIpsx0vTR3a12e2hp_4EfiO_hBnnUZaChLgl8kR27JnxeDzzDcBbGY76RqIAKt13gVDaBFqgMlRGc5XI1KaacoeHH-XxF3Fy1j9bgndtLkyND9E53EgyvL4mAdem2r8HDS0uLB4404QSfaNYEm7--88ddBQZOg0CcxjgQUy2qEIh3---XNyLHhiYD-Mkf7Vf_QZ0tApf26HXcSeXe_OZ2bO3v6E6_ue_rcGTxjBlBzUnPYUlV67DyrC5en8Gl4Nian2tr_Ibuy6mP-6-xzzUbOLj-VzFCso0GVfzSR1ae-PYtab6YOeosSo25Iyiycbk8mW64QmXM_IDsyvUOMwS_00Zxbo_h9Ojw9PBcdBUagisEKgxeeTQEJTSmSSy3KXaaJVzwsGJjRyJPBcRl0qgRhMmdlpZi685D0fWxWmexC9guRyX7hWwRMo8NCbMkxR1i4i0tQl3CZGj5WJlD3bbJctsg2JOxTSushp_mWc4d5mfux686UgnNXTHn4i22nXPGumtMs7DmKDAeNSD110zyh1dpujSjedIg4d7IQjArwcvazbpeiEXkRQKW9QCA3UEhOm92FIW5x7bWxKcjsR-dz1__H3g2YeTgX_Y-HfSTXiM9l5aR7ptwfJsOnfbaFPNzA484uLTjhehnxcSIKg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NTtwwEB5RKrVcKvpHt6WtqXrgEpE4XtuRekGrooWyiMNW4hbZjhdCIbvaZTnzCDwjT8KMk01ZQaXeEnkiRx7P-PN4_A3AdxmPulaiASrT9ZFQxkZGoDNU1nClZeYyQ3eHB0ey_1scnHRPVuDH4i5MzQ_RBtzIMoK_JgOngPTOX9bQ8tzhjjPT-hk8F4jLiTmfi-P2DAGhTsPBHEe4FZMLXqGY77SfLq9GjyDm40zJhwg2LEF76_CqwY5st1b2a1jx1Rt4MWhOx9_Cn145daEcV3XKLsvp3c1tymPDJiHlzs9YSZdBxrP5pM5-vfbs0lAJrzN0KjM24IwSvsYUlWWmUZsvGIVq2QU6BeZoikwZpaO_g-Hez2GvHzXFFCInBDo1nnjEalJ6qxPHfWasUQUnqprUypEoCpFwqQQ6HWFTb5Rz-FrweOR8mhU6fQ-r1bjyH4BpKYvY2rjQGZq_SIxzmntN4ggunOzA9mJMc9cQjVO9i4u8pkjmOQ5_Hoa_A99a0UnNrvGU0OZCMXljYLOc8zglti6edGCrbUbToPMOU_nxHGVw_y0Ecex1YKPWY9sLRXGkUNiiljTcChDt9nJLVZ4F-m1JjDcS-90Oc-HfP57vH_TCw8f_F_0KL_vDwWF-uH_06xOsITzL6sS0TVi9ms79Z4RAV_ZLmOn35XYDOA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwEB6VVqq4IMrvQgGDOPQSNXG8tqOe0JZVW9iqhyL1FvlvaaDNrna7nHkEnpEn6YyTDV21lbgl8kSOPJ7x5_H4G4CPMh33rUQDVKYfEqGMTYxAZ6is4UrLwhWG7g6PjuXBN3F01j9bg73lXZiGH6ILuJFlRH9NBj71491_pKHVD4cbzkLrB7BBh31Ut4GLk-4IAZFOS8GcJrgTk0taoZTvdp-uLka3EObtRMmbADauQMPH8KiFjuxTo-stWAv1E9gctYfjT-HnoJq5WI2r_s4uq9nf339ynho2jRl3Yc4qugsymS-mTfLrr8AuDVXwOkefMmcjzijfa0JBWWZarQXPKFLLLtAnMEczZMYoG_0ZnA4_nw4OkraWQuKEQJ_Gs4BQTcpgdeZ4KIw1ynNiqsmtHAvvRcalEuhzhM2DUc7hq-fp2IW88Dp_Duv1pA4vgWkpfWpt6nWB1i8y45zmQZM4Ygsne7CzHNPStTzjVO7iomwYknmJw1_G4e_Bh0502pBr3CW0vVRM2drXvOQ8zYmsi2c9eN81o2XQcYepw2SBMrj9FoIo9nrwotFj1wsFcaRQ2KJWNNwJEOv2aktdnUf2bUmENxL73Ylz4f4fLw-PBvHh1f-LvoPNk_1h-fXw-MtreIjgrGjS0rZh_Wq2CG8QAF3Zt3GiXwNKIwJh
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+mir%E2%80%90320a+promotes+immunosuppressive+macrophages+M2+phenotype+associated+with+lung+cancer+risk&rft.jtitle=International+journal+of+cancer&rft.au=Fortunato%2C+Orazio&rft.au=Borzi%2C+Cristina&rft.au=Milione%2C+Massimo&rft.au=Centonze%2C+Giovanni&rft.date=2019-06-01&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=144&rft.issue=11&rft.spage=2746&rft.epage=2761&rft_id=info:doi/10.1002%2Fijc.31988&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_ijc_31988
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon